NasdaqGM - Delayed Quote USD

CRISPR Therapeutics AG (CRSP)

Compare
51.62 -0.26 (-0.50%)
At close: 4:00 p.m. EST
51.62 0.00 (0.00%)
After hours: 6:25 p.m. EST
Advanced Chart
Loading Chart for CRSP
DELL
  • Previous Close 51.88
  • Open 51.21
  • Bid 51.47 x 800
  • Ask 51.68 x 400
  • Day's Range 50.60 - 52.52
  • 52 Week Range 43.42 - 91.10
  • Volume 1,304,093
  • Avg. Volume 1,115,276
  • Market Cap (intraday) 4.406B
  • Beta (5Y Monthly) 1.66
  • PE Ratio (TTM) --
  • EPS (TTM) -2.79
  • Earnings Date Nov 5, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 79.83

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

www.crisprtx.com

407

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about CRISPR Therapeutics AG

Recent News: CRSP

View More
View More

Related Videos: CRSP

Elon Musk will be 'vitally important' in Trump admin: Cathie Wood

M&A could be back on the menu for companies looking forward to a second Donald Trump presidency — major banks anticipate a slew of beneficial deregulations while Big Tech believes it has found a new friend in its antitrust battles with the Federal Trade Commission (FTC). To expand more upon how Corporate America is interpreting Trump's 2024 election victory over Vice President Kamala Harris, ARK Investment Management CEO and CIO Cathie Wood sits down with Julie Hyman and Josh Lipton on Market Domination Overtime. Wood's firm manages the ARK Innovation ETF (ARKK), which has a variety of holdings in tech players like Tesla (TSLA), Palantir Technologies (PLTR), and Coinbase Global (COIN). Wood calls Securities and Exchange Commission (SEC) Chair Gary Gensler "a menace" to crypto-adoption in the US, and says replacing FTC Chair Lina Khan will "break the M&A logjam" for most companies. "I think venture capital has been harmed dramatically in the last few years, for lack of liquidity events. Liquidity events, very importantly, involve mergers and acquisitions, and those ground to a halt, even in mergers or deals where the two companies were not competing with each other," Wood tells Yahoo Finance. A long-time supporter of Tesla (TSLA) CEO Elon Musk, Wood believes he will play a "vitally important role" in Trump's government efficiency initiative while remaining "focused" on the plethora of companies he owns. "As he says, and I've always believed, government spending is taxation, and we are bloated right now. We're just overwhelmed with taxation as well," Wood explains. "So I think that he's going to be really important in two ways — introducing new technologies, and actually cutting out a lot of middlemen in the government, just like he did at Twitter." Tesla currently makes up 14.21% of the ARK Innovation ETF, the holdings worth just over $900 million. Wood is forecasting Tesla stock to reach $2,600 in five years time; while confident in the EV maker's ability to bring safe fully autonomous vehicles to market, she disagrees that Tesla's most recent stock jump has to do with Musk's affiliation with Trump. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. This post was written by Luke Carberry Mogan.
Yahoo Finance Video · 1 hr ago
BTC-USD
+0.71%
ARKK
+2.62%

Performance Overview: CRSP

Trailing total returns as of 2024-11-08, which may include dividends or other distributions. Benchmark is

.

YTD Return

CRSP
17.54%
S&P 500
25.70%

1-Year Return

CRSP
11.88%
S&P 500
36.94%

3-Year Return

CRSP
42.80%
S&P 500
27.63%

5-Year Return

CRSP
5.33%
S&P 500
94.33%

Compare To: CRSP

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

CRSP
CRISPR Therapeutics AG
51.62
-0.50%
Mkt Cap 4.406B
Industry Biotechnology
VRTX
Vertex Pharmaceuticals Incorporated
516.74
+2.84%
Mkt Cap 133.076B
Industry Biotechnology
NTLA
Intellia Therapeutics, Inc.
16.73
+4.56%
Mkt Cap 1.699B
Industry Biotechnology
BEAM
Beam Therapeutics Inc.
27.06
+3.68%
Mkt Cap 2.241B
Industry Biotechnology
VKTX
Viking Therapeutics, Inc.
68.48
-0.54%
Mkt Cap 7.631B
Industry Biotechnology
EDIT
Editas Medicine, Inc.
3.1200
-1.58%
Mkt Cap 257.55M
Industry Biotechnology
MRNA
Moderna, Inc.
46.83
-6.86%
Mkt Cap 18.021B
Industry Biotechnology
MDGL
Madrigal Pharmaceuticals, Inc.
350.70
-1.17%
Mkt Cap 7.649B
Industry Biotechnology
RXRX
Recursion Pharmaceuticals, Inc.
7.10
+2.45%
Mkt Cap 2.035B
Industry Biotechnology
TGTX
TG Therapeutics, Inc.
28.81
+3.26%
Mkt Cap 4.46B
Industry Biotechnology
TNYA
Tenaya Therapeutics, Inc.
2.7600
+10.40%
Mkt Cap 217.734M
Industry Biotechnology

Statistics: CRSP

View More

Valuation Measures

As of 2024-11-07

  • Market Cap

    4.43B

  • Enterprise Value

    2.72B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    21.51

  • Price/Book (mrq)

    2.28

  • Enterprise Value/Revenue

    13.60

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -118.13%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    202.83M

  • Net Income Avi to Common (ttm)

    -239.59M

  • Diluted EPS (ttm)

    -2.79

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2B

  • Total Debt/Equity (mrq)

    11.68%

  • Levered Free Cash Flow (ttm)

    --

View More

Research Analysis: CRSP

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 602k
Earnings -85.94M
Q4'23
Q1'24
Q2'24
Q3'24
-100M
0
100M
200M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

30.00
79.83 Average
51.62 Current
199.00 High
 
View More

People Also Watch

EDIT Editas Medicine, Inc.
3.1200
-1.58%
 
NTLA Intellia Therapeutics, Inc.
16.73
+4.56%
 
TDOC Teladoc Health, Inc.
9.23
-2.94%
 
PACB Pacific Biosciences of California, Inc.
2.3000
-6.12%
 
BEAM Beam Therapeutics Inc.
27.06
+3.68%
 
ILMN Illumina, Inc.
151.09
-2.62%
 
VRTX Vertex Pharmaceuticals Incorporated
516.74
+2.84%
 
U Unity Software Inc.
20.50
-7.70%
 
SQ Block, Inc.
74.56
-0.94%
 
ROKU Roku, Inc.
73.82
+2.49%
 
TWLO Twilio Inc.
92.29
-0.13%
 
SNOW Snowflake Inc.
120.89
-2.15%
 
LMND Lemonade, Inc.
28.44
+4.06%
 
DOCU DocuSign, Inc.
79.38
+3.81%
 
CRWD CrowdStrike Holdings, Inc.
330.03
-0.23%
 
QS QuantumScape Corporation
5.02
+0.60%